Research ArticleINFLAMMATION

Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases

See allHide authors and affiliations

Science Immunology  30 Apr 2021:
Vol. 6, Issue 58, eabe2933
DOI: 10.1126/sciimmunol.abe2933

Article Information

vol. 6 no. 58

PubMed: 
Published By: 
History: 
  • Received August 12, 2020
  • Revision received February 3, 2021
  • Accepted March 23, 2021
  • .

Author Information

  1. Guang-Ming Ren1,
  2. Jian Li2,
  3. Xiao-Chun Zhang3,
  4. Yu Wang1,4,
  5. Yang Xiao1,
  6. Xuan-Yi Zhang1,
  7. Xian Liu1,
  8. Wen Zhang1,5,
  9. Wen-Bing Ma1,
  10. Jie Zhang1,5,
  11. Ya-Ting Li1,5,
  12. Shou-Song Tao1,5,
  13. Ting Wang1,4,
  14. Kai Liu1,
  15. Hui Chen1,
  16. Yi-Qun Zhan1,
  17. Miao Yu1,
  18. Chang-Yan Li1,
  19. Chang-Hui Ge2,
  20. Bo-Xue Tian3,
  21. Gui-Fang Dou2,
  22. Xiao-Ming Yang1,4,* and
  23. Rong-Hua Yin1,*
  1. 1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
  2. 2Beijing Institute of Radiation Medicine, Beijing 100850, China.
  3. 3School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.
  4. 4School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, Anhui, China.
  5. 5Department of Pharmaceutical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
  1. *Corresponding author. Email: xiaomingyang{at}sina.com (X.-M.Y.); yrh1980110{at}126.com (R.-H.Y.)

Altmetric

Article usage

Article usage: April 2021 to May 2021

AbstractFullPdf
Apr 20216477918
May 20217367544268

Stay Connected to Science Immunology